CD274 and non-small cell lung carcinoma: At the present time, the only clinically validated first-line biomarker for determining eligibility for PD1/PD-L1 ICIs for patients with advanced NSCLC is PD-L1 expression by IHC on formalin-fixed, paraffin-embedded (FFPE) sections.